Factor H-Fc immunotheraphy
US10975131B2 · kind B2 · utility
1Cited by
10References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2016 |
| Grant date | Apr 13, 2021 |
| Priority date | — |
| Expiry date | Oct 27, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fusion proteins comprising human FH domains 18-20 (FH18-20) linked via an optional linker to IgG Fc, wherein the FH has mutation of D to G at position 1119 in domain 19; FHD1119G/Fc), and methods of use thereof, e.g., to treat pathogen infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.